article thumbnail

Improper Medicare payments down $20.7B since 2014, CMS data show

Fierce Healthcare

since 2014, CMS data show. Improper Medicare payments down $20.7B Tue, 11/16/2021 - 07:15.

129
129
article thumbnail

Medicaid coverage for substance abuse treatment improved substantially since 2014: study

Fierce Healthcare

Access to care for Medicaid fee-for-service beneficiaries with substance use disorder has improved from 2014 until 2021, but much more can be done to improve it further, researchers say. There have been substantial improvements in coverage for substance use disorder and opioid use disorder since 2014, according to a study in JAMA Network.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Publishing virtually every GDUFA guidance and MAPP since 2014 to fulfill FDAs GDUFA commitments.

FDA 144
article thumbnail

What the 2014 Ebola outbreak taught this biotech CEO about persuasion

PharmaVoice

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

130
130
article thumbnail

FDA Approves Pembrolizumab Plus Chemoradiotherapy to Treat FIGO 2014 Stage III-IVA Cervical Cancer

Pharmacy Times

The approval was based on the results of a phase 3 trial that found an improvement in progression-free survival among individuals treated with pembrolizumab.

FDA 123
article thumbnail

2024 IDstewardship Year End Review

IDStewardship

Steven Smoke, Pharm.D., BCIDP, BCPT Five Things To Know: How To Use Artificial Intelligence To Be A Better Clinical Pharmacist Katarzyna Wojcik, PMP, PhD,Andrea Prinzi, PhD, MPH, CPH, SM(ASCP),Amanda Suchanek, Ph.D., Jessica Blavignac Microbiology Laboratory Strategies to Advance Antimicrobial Stewardship Timothy Gauthier, Pharm.D.,

article thumbnail

FDA Approves IgG-Hyaluronidase Recombinant for the Treatment of Adult Patients With CIDP

Pharmacy Times

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

FDA 145